All In Biotech

Drug Trial Radar · NCT02302066

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America

Last checked: Nov 19, 2026Latest source record: Feb 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,800

Actual

Start

Dec 5, 2014

Primary completion

Feb 18, 2019

Study completion Feb 18, 2019

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 26, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and \<18 years of age living in dengue endemic countries.

Conditions

  • Dengue Fever

Interventions

  • Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Biological

    TDV subcutaneous injection

  • TDV PlaceboBiological

    Placebo-matching vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers (GMTs) of Neutralizing Antibodies (Microneutralization Test [MNT50]) for Each of the Four DENV Serotypes for Participants in the Immunogenicity SubsetTime frame: Up to Month 48

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Hospital Maternidad Nuestra Senora de la Altagracia

    Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic

  • Centro De Vacunacion Internacional, S.A.(CEVAXIN)

    Panama City, Panama

  • Dela Salle Health Sciences Institute

    Dasmariñas, Cavite, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.